Inflammatory Arthritis: An Overview for Primary Care Physicians

References

• . Bergman MJ. Social and economic impact of inflammatory arthritis. Postgrad Med. 2006; Spec No:5–11
   Google Scholar
• . US Department of Health and Human Services and the Centers for Disease Control and Prevention Coordinating Center for Health Promotion. Targeting arthritis. Reducing disability for 43 million Americans 2005. Atlanta, GA: CDC; 2005
   Google Scholar
• . Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–136
   PubMed Web of Science ®Google Scholar
• . Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol. 2004;69( suppl):3–8
   Google Scholar
• . Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis—development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007;34(3):481–487
   PubMed Web of Science ®Google Scholar
• . Geuskens GA, Burdorf A, Hazes JM. Consequences of rheumatoid arthritis for performance of social roles—a literature review. J Rheumatol. 2007;34(6):1248–1260
   PubMed Web of Science ®Google Scholar
• . Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Disease activity score—28 values differ considerably depending on patient's pain perception and sex. J Rheumatol. 2007;34(12):2382–2387
   PubMed Web of Science ®Google Scholar
• . Dellhag B, Bjelle A. A five-year followup of hand function and activities of daily living in rheumatoid arthritis patients. Arthritis Care Res. 1999;12(1):33–41
   PubMed Web of Science ®Google Scholar
• . Odegård S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol. 2005;34(6):441–447
   PubMed Web of Science ®Google Scholar
• . Odegård S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1195–1201
   PubMed Web of Science ®Google Scholar
• . Feldman DE, Bernatsky S, Haggerty J,. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. Arthritis Rheum. 2007;57(8):1419–1425
   PubMedGoogle Scholar
• . Harrison MJ, Tricker KJ, Davies L,. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol. 2005;32(12):2330–2336
   PubMed Web of Science ®Google Scholar
• . Jacobi CE, Mol GD, Boshuizen HC, Rupp I, Dinant HJ, Van Den Bos GA. Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services. Arthritis Rheum. 2003;49(4):567–573
   PubMedGoogle Scholar
• . Marra CA, Lynd LD, Esdaile JM, Kopec J, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. Rheumatology(Oxford). 2004;43(11):1390–1397
   PubMed Web of Science ®Google Scholar
• . Groessl EJ, Ganiats TG, Sarkin AJ. Sociodemographic differences in quality of life in rheumatoid arthritis. Pharmacoeconomics. 2006; 24(2):109–121
   PubMed Web of Science ®Google Scholar
• . Maiden N, Capell HA, Madhok R, Hampson R, Thomson EA. Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis. 1999;58(9):525–529
   PubMed Web of Science ®Google Scholar
• . Allaire S, Wolfe F, Niu J, LaValley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum. 2008;59(4):474–480
   PubMed Web of Science ®Google Scholar
• . Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003;17(5):729–752
   PubMed Web of Science ®Google Scholar
• . Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35(1):8–17
   PubMed Web of Science ®Google Scholar
• . Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol. 2005;17(3):234–241
   PubMed Web of Science ®Google Scholar
• . Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740–1751
   PubMed Web of Science ®Google Scholar
• . Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol. 2004;16(3):254–261
   PubMed Web of Science ®Google Scholar
• . Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66(3):308–312
   PubMed Web of Science ®Google Scholar
• . Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29(2):147–155
   PubMed Web of Science ®Google Scholar
• . Bazzichi L, Maser J, Piccinni A,. Quality of life in rheumatoid arthritis: impact of disability and lifetime depressive spectrum symptomatology. Clin Exp Rheumatol. 2005;23(6):783–788
   PubMed Web of Science ®Google Scholar
• . Kosinski M, Kujawski SC, Martin R,. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care. 2002;8(3):231–240
   PubMed Web of Science ®Google Scholar
• . West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheumatol. 2005;24(2):117–122
   PubMed Web of Science ®Google Scholar
• . Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61( suppl 3):iii8–iii18
   PubMed Web of Science ®Google Scholar
• . Kataria RK, Brent LH. Spondyloarthropathies. Am Fam Physician. 2004;69(12):2853–2860
   PubMed Web of Science ®Google Scholar
• . Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000;27(3):613–622
   PubMed Web of Science ®Google Scholar
• . Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4–11
   PubMedGoogle Scholar
• . Dagfinrud H, Kjeken I, Mowinckel P, Hagen KB, Kvien TK. Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol. 2005;32(3):516–523
   PubMed Web of Science ®Google Scholar
• . Zink A, Thiele K, Huscher D,. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(1):86–90
   PubMed Web of Science ®Google Scholar
• . Song IH, Sieper J, Rudwaleit M. Diagnosing early ankylosing spondylitis. Curr Rheumatol Rep. 2007;9(5):367–374
   PubMedGoogle Scholar
• . Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum. 2005;53(1):5–11
   PubMed Web of Science ®Google Scholar
• . Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–2172
   PubMed Web of Science ®Google Scholar
• . Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH. Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum. 2008;59(4):497–503
   PubMed Web of Science ®Google Scholar
• . Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol. 2005;32(4):721–728
   PubMed Web of Science ®Google Scholar
• . Ozgul A, Peker F, Taskaynatan MA,. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol. 2006;25(2):168–174
   PubMed Web of Science ®Google Scholar
• . Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006;24(5):438–447
   PubMed Web of Science ®Google Scholar
• . Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64( suppl 2):ii14–ii17
   PubMed Web of Science ®Google Scholar
• . Neimann AL, Shin DB, Wang X,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–835
   PubMed Web of Science ®Google Scholar
• . Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328
   PubMed Web of Science ®Google Scholar
• . Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28(8):1842–1846
   PubMed Web of Science ®Google Scholar
• . de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140–147
   PubMed Web of Science ®Google Scholar
• . Krueger G, Koo J, Lebwohl M,. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–284
   PubMed Web of Science ®Google Scholar
• . van der Heijde DM, van 't Hof MA, van Riel PL,. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916–920
   PubMed Web of Science ®Google Scholar
• . Smolen JS, Breedveld FC, Schiff MH,. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244–257
   PubMed Web of Science ®Google Scholar
• . Aletaha D, Nell VP, Stamm T,. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–R806
   PubMed Web of Science ®Google Scholar
• . Felson DT, Anderson JJ, Boers M,. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–735
   PubMed Web of Science ®Google Scholar
• . Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998;41(9):1564–1570
   PubMedGoogle Scholar
• . van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34–40
   PubMed Web of Science ®Google Scholar
• . Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 suppl 39):S93–S99
   PubMed Web of Science ®Google Scholar
• . Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exper Rheumatol. 2006;24(6 suppl 43):S22–S28
   Web of Science ®Google Scholar
• . Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981;24(10):1308–1315
   PubMed Web of Science ®Google Scholar
• . Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996;35(11):1101–1105
   PubMedGoogle Scholar
• . van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 2000;59( suppl 1):i28–i31
   PubMed Web of Science ®Google Scholar
• . McQueen FM, Ostergaard M. Established rheumatoid arthritis—new imaging modalities. Best Pract Res Clin Rheumatol. 2007;21(5):841–856
   PubMed Web of Science ®Google Scholar
• . Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford). 1999;38(9):878–882
   PubMed Web of Science ®Google Scholar
• . Calin A, Garrett S, Whitelock H,. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281–2285
   PubMed Web of Science ®Google Scholar
• . Zochling J, Braun J. Remission in ankylosing spondylitis. Clin Exp Rheumatol. 2006;24(6 suppl 43):S88–S92
   Web of Science ®Google Scholar
• . Baraliakos X, Brandt J, Listing J,. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 2005;53(6):856–863
   PubMedGoogle Scholar
• . Baraliakos X, Listing J, Brandt J,. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439–R444
   PubMed Web of Science ®Google Scholar
• . Brandt J, Khariouzov A, Listing J,. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6): 1667–1675
   PubMed Web of Science ®Google Scholar
• . Brandt J, Listing J, Haibel H,. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005;44(3):342–348
   PubMed Web of Science ®Google Scholar
• . Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. Clin Rheumatol. 2000;19(1):51–57
   PubMed Web of Science ®Google Scholar
• . Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol. 1999;26(9):1953–1958
   PubMed Web of Science ®Google Scholar
• . Kavanaugh A, Cassell S. The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol. 2005;23(5 suppl 39):S142–S147
   PubMed Web of Science ®Google Scholar
• . Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004;50(1):24–35
   PubMed Web of Science ®Google Scholar
• . Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A,. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62(2):127–132
   PubMed Web of Science ®Google Scholar
• . Taylor WJ. Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol. 2004;16(4):350–356
   PubMed Web of Science ®Google Scholar
• . Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581–587
   PubMed Web of Science ®Google Scholar
• . Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol. 2006;24(6 suppl 43):S83–S87
   PubMed Web of Science ®Google Scholar
• . Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol. 2006;24(6 suppl 43):S7–S13
   PubMed Web of Science ®Google Scholar
• . Keystone EC. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists—an opportunity to improve outcomes. Nat Clin Pract Rheumatol. 2006;2(11):594–601
   PubMedGoogle Scholar
• . Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005;19(1):163–177
   PubMed Web of Science ®Google Scholar
• . Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005;52(4):1009–1019
   PubMedGoogle Scholar
• . Breedveld FC, Weisman MH, Kavanaugh AF,. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37
   PubMed Web of Science ®Google Scholar
• . Klareskog L, van der Heijde D, de Jager JP,. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–681
   PubMed Web of Science ®Google Scholar
• . St Clair EW, van der Heijde DM, Smolen JS,. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–3443
   PubMed Web of Science ®Google Scholar
• . Kremer JM, Westhovens R, Leon M,. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907–1915
   PubMed Web of Science ®Google Scholar
• . Kremer JM, Genant HK, Moreland LW,. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865–876
   PubMed Web of Science ®Google Scholar
• . Kremer JM, Dougados M, Emery P,. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(8):2263–2271
   PubMed Web of Science ®Google Scholar
• . Emery P, Fleischmann R, Filipowicz-Sosnowska A,. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–1400
   PubMed Web of Science ®Google Scholar
• . Cohen SB, Emery P, Greenwald MW,. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–2806
   PubMed Web of Science ®Google Scholar
• . Keystone EC, Emery P, Peterfy CG,. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. Published online. April 3, 2008
   Google Scholar
• . Nishimoto N, Hashimoto J, Miyasaka N,. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–1167
   PubMed Web of Science ®Google Scholar
• . Smolen JS, Beaulieu A, Rubbert-Roth A,. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997
   PubMed Web of Science ®Google Scholar
• . Nagle M. Amgen expounds IL-17 potential as arthritis target. http://www.drugresearcher.com/news/ng.asp?n=79206-amgen-wyeth-inflammation-il-arthritis. Accessed May 16, 2008
   Google Scholar
• . Geboes L, Dumoutier L, Kelchtermans H,. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009;60(2):390–395
   PubMed Web of Science ®Google Scholar
• . Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol. 2008;20(3):257–262
   PubMed Web of Science ®Google Scholar
• . Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285): 903–911
   PubMed Web of Science ®Google Scholar
• . van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol. 1995;22(9):1792–1796
   PubMed Web of Science ®Google Scholar
• . Lard LR, Visser H, Speyer I,. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111(6):446–451
   PubMed Web of Science ®Google Scholar
• . Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum. 2008;59(4): 510–514
   PubMedGoogle Scholar
• . Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20(5):849–863
   PubMed Web of Science ®Google Scholar
• . Möttönen T, Hannonen P, Korpela M,. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46(4):894–898
   PubMed Web of Science ®Google Scholar
• . Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann, M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43(7):906–914
   PubMed Web of Science ®Google Scholar
• . Grigor C, Capell H, Stirling A,. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–269
   PubMed Web of Science ®Google Scholar
• . Möttönen T, Hannonen P, Leirisalo-Repo M,. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353(9164):1568–1573
   PubMed Web of Science ®Google Scholar
• . Leirisalo-Repo M, Kautiainen H, Laasonen L,. A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACO DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACO study [abstract OP-0009]. Ann Rheum Dis. 2008;67( suppl II):50
   Google Scholar
• . Smolen JS, van der Heijde DM, St Clair EW,. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702–710
   PubMed Web of Science ®Google Scholar
• . Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF,. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–3390
   PubMed Web of Science ®Google Scholar
• . van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK,. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2008;67(2):266–269
   PubMed Web of Science ®Google Scholar
• . Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33(7):1422–1430
   PubMed Web of Science ®Google Scholar
• . Kahn KL, MacLean CH, Liu H,. The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease care. Med Care. 2007;45(1):55–65
   PubMed Web of Science ®Google Scholar
• . Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum. 2005;53(2):241–248
   PubMedGoogle Scholar
• . Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002;61(4):290–297
   PubMed Web of Science ®Google Scholar
• . Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23(2):61–66
   PubMed Web of Science ®Google Scholar
• . Zochling J, Braun J. Quality indicators, guidelines and outcome measures in ankylosing spondylitis. Clin Exp Rheumatol. 2007; 25(6 suppl 47):147–152
   PubMed Web of Science ®Google Scholar
• . Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64(5):659–663
   PubMed Web of Science ®Google Scholar
• . Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–2673
   PubMed Web of Science ®Google Scholar
• . Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43(2):143–147
   PubMed Web of Science ®Google Scholar
• . Trexall [package insert]. Pamona, NY: Barr Laboratories, Inc; 2005
   Google Scholar
• . Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006;20(6):1181–1195
   PubMed Web of Science ®Google Scholar
• . Baecklund E, Iliadou A, Askling J,. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701
   PubMed Web of Science ®Google Scholar
• . Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–1439
   PubMed Web of Science ®Google Scholar
• . Mayo Clinic Staff. Non-Hodgkin's lymphoma. Mayo Foundation for Medical Education and Research. http://www.mayoclinic.com/health/non-hodgkins-lymphoma/DS00350/DSECTION=symptoms. Accessed February 3, 2009
   Google Scholar
• . Nicola PJ, Maradit-Kremers H, Roger VL,. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412–420
   PubMed Web of Science ®Google Scholar
• . Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116(5):305–311
   PubMed Web of Science ®Google Scholar
• . Humira (adalimumab) [package insert]. North Chicago, IL: Abbott Laboratories; 2007
   Google Scholar
• . Remicade (infliximab) [package insert]. Malvern, PA: Centocor, Inc; 2007
   Google Scholar
• . Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals; 2008
   Google Scholar
• . Orencia (abatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2007
   Google Scholar
• . Rituxan (rituximab) [package insert]. San Francisco, CA: Genentech, Inc; 2008
   Google Scholar
• . Feinstein DE, Brent LH. The complexity of the differential diagnosis for the inflammatory arthritides. Postgrad Med. 2006; Spec No:12–23
   Google Scholar
• . Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–1390
   PubMed Web of Science ®Google Scholar
• . Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum. 1999;28(6):368–391
   PubMed Web of Science ®Google Scholar
• . Walsh B, Yocum DE, Khan MA. Arthritis and HLA-B27 in native North American tribes. Curr Opin Rheumatol. 1998;10(4):319–325
   PubMedGoogle Scholar
• . Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62(17):2447–2457
   PubMed Web of Science ®Google Scholar
• . Ritchie DM, Boyle JA, McInnes JM,. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968;37(147):393–406
   PubMedGoogle Scholar
• . Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48
   PubMed Web of Science ®Google Scholar
• . Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol. 2006;24(6 suppl 43):S29–S32
   Web of Science ®Google Scholar
• . van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845–1850
   PubMed Web of Science ®Google Scholar
• . Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876–1886
   PubMed Web of Science ®Google Scholar
• . Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438–1444
   PubMed Web of Science ®Google Scholar
• . Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244
   PubMedGoogle Scholar
• . Verstappen SM, Jacobs JW, van der Veen MJ,. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443–1449
   PubMed Web of Science ®Google Scholar
• . Emery P, Breedveld FC, Hall S,. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–382
   PubMed Web of Science ®Google Scholar